Abstract
Despite improvements in first-line therapy for advanced NSCLC all patients with metastatic disease will progress at some point. Patients with favorable prognostic factors such as good performance status, non-squamous histology, stable weight, and perhaps female gender are more likely to receive second-line chemotherapy. Currently the United States FDA recognizes three single agents (docetaxel, erlotinib, and pemetrexed) as established for providing a benefit in patients who have experienced progression after first-line therapy. This review focuses on the role of PEM in the treatment of advanced NSCLC in patients who have experienced disease progression during or after first-line therapy. The multi-targeted antifolate pemetrexed is equivalent to docetaxel for second-line therapy and with less toxicity.
Keywords: Advanced non-small cell lung cancer, second-line chemotherapy, pemetrexed
Current Drug Targets
Title: The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer
Volume: 11 Issue: 1
Author(s): Steven Tucker
Affiliation:
Keywords: Advanced non-small cell lung cancer, second-line chemotherapy, pemetrexed
Abstract: Despite improvements in first-line therapy for advanced NSCLC all patients with metastatic disease will progress at some point. Patients with favorable prognostic factors such as good performance status, non-squamous histology, stable weight, and perhaps female gender are more likely to receive second-line chemotherapy. Currently the United States FDA recognizes three single agents (docetaxel, erlotinib, and pemetrexed) as established for providing a benefit in patients who have experienced progression after first-line therapy. This review focuses on the role of PEM in the treatment of advanced NSCLC in patients who have experienced disease progression during or after first-line therapy. The multi-targeted antifolate pemetrexed is equivalent to docetaxel for second-line therapy and with less toxicity.
Export Options
About this article
Cite this article as:
Tucker Steven, The Role of Pemetrexed in Second-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer, Current Drug Targets 2010; 11 (1) . https://dx.doi.org/10.2174/138945010790031036
DOI https://dx.doi.org/10.2174/138945010790031036 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Long Noncoding RNA MALAT1: Insights into its Biogenesis and Implications in Human Disease
Current Pharmaceutical Design Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Molecular Kinetics and Targeting Within the Nucleus
Current Chemical Biology Feasibility of FDG PET in Inflammatory Bowel Disease
Current Molecular Imaging (Discontinued) Gastrin-Releasing Peptide Receptors Regulate Proliferation of C6 Glioma Cells through a Phosphatidylinositol 3-Kinase-Dependent Mechanism
Current Neurovascular Research Enzyme Inhibition as a Key Target for the Development of Novel Metal-Based Anti-Cancer Therapeutics
Anti-Cancer Agents in Medicinal Chemistry Histotype in Non-Small Cell Lung Cancer Therapy and Staging: The Emerging Role of an Old and Underrated Factor
Current Respiratory Medicine Reviews Regulatory T Cell Counts and Development of Malignancy in Patients with HIV Infection
Current HIV Research Influence of CYP2D6 Genetics on Opioid Kinetics, Metabolism and Response
Current Pharmacogenomics Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform
Protein & Peptide Letters Characterization and in vitro Cytotoxicity Evaluation of Meloxicam Loaded PEGylated Mixed Micelles Fabricated Using Quality by Design Approach
Drug Delivery Letters The De Novo Synthesis of Oligosaccharides: Application to the Medicinal Chemistry SAR-Study of Digitoxin
Current Topics in Medicinal Chemistry 3D-QSAR and Docking Studies on Pyrimidine Derivatives as CSF-1R Inhibitors
Letters in Drug Design & Discovery Genetic and Modifying Factors that Determine the Risk of Brain Tumors
Central Nervous System Agents in Medicinal Chemistry Cytokine Antibody Arrays in Biomarker Discovery and Validation
Current Proteomics Construction and Validation of a Nomogram for Predicting Progression- Free Survival in Patients with Early-Stage Testicular Germ Cell Tumor
Recent Patents on Anti-Cancer Drug Discovery Peptide Vaccines for Cancer Therapy
Recent Patents on Inflammation & Allergy Drug Discovery Cadmium and Its Epigenetic Effects
Current Medicinal Chemistry Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery The Need for Physiologically Relevant Peroxisome Proliferator-Activated Receptor-gamma (PPAR-γ) Ligands
Endocrine, Metabolic & Immune Disorders - Drug Targets